Improving the treatment of Epstein-Barr virus infectious mononucleosis in children
Keywords:children, infectious mononucleosis, Epstein-Barr infection, liver, ursodeoxycholic acid
AbstractBackground. In Ukraine, as in the whole world, there is a tendency to increase in the number of diffuse liver diseases. Increased percentage of patients with liver disease among adults is mostly determined by the damages to hepatobiliary system in childhood. The purpose of the study was to evaluate the effectiveness of ursodeoxycholic acid (UDCA) in the therapy of liver damages due to Epstein-Barr virus (EBV). Materials and methods. Research design: prospective, open-label, controlled. Sixty children with EBV infectious mononucleosis (IM) aged 1 to 18 years old were screened. All patients were observed, examined during the acute period of the disease, and divided into 2 groups. The children of the main group (n = 35) received standard therapy for EBV IM in combination with UDCA, patients of the control group (n = 25) received standard treatment alone. Results. Received data showed that therapy improved by means of UDCA in EBV IM and liver damage promotes a faster regression of the main symptoms of infection, such as fever, appetite loss and jaundice, already on day 7 from the beginning of treatment and a more rapid normalization of indicators of the functional state of the liver (alanine aminotransferase, bilirubin, alkaline phosphatase, gamma glutamyltransferase, lactate dehydrogenase). The drug was well tolerated, no adverse reactions were observed. Conclusions. The inclusion of UDCA in the treatment scheme can improve the effectiveness of advanced therapy compared with standard one, promotes a more rapid regression of infection symptoms and a more rapid normalization of indicators of the functional state of the liver.
Kramarev SA, Litvinenko NG, Palatnaia LA. Epstein-Barr virus infection in children. Sovremennaya pediatriya.2004;(34):13-18. (in Russian).
Feranchak AP, Tyson RW, Narkewicz MR, Karrer FM, Sokol RJ. Fulminant Epstein-Barr viral hepatitis: orthotopic liver transplantation and review of the literature. Liver Transpl Surg. 1998 Nov;4(6):469-76.
Maeda A, Wakiguchi H, Yokoyama W, Hisakawa H, Tomoda T, Kurashige T. Persistently high Epstein-Barr virus (EBV) loads in peripheral blood lymphocytes from patients with chronic active EBV infection. J Infect Dis. 1999 Apr;179(4):1012-5. doi: 10.1086/314691.
Volkova GI. Epshteina-Barr virusnyi gepatit u detei. Diss. kand. med. nauk [Epstein-Barr virus hepatitis in children. PhD diss.]. Moscow; 2013. 20 p. (in Russian).
Friedman SL, Maher JJ, Bissell DM. Mechanisms and therapy of hepatic fibrosis: report of the AASLD Single Topic Basic Research Conference. Hepatology. 2000 Dec;32(6):1403-8. doi: 10.1053/jhep.2000.20243.
Urazova OI, Pomogaeva AP, Novitsky VV, Potarskaya EV, Shevtsova NM. Subpopulation composition and metabolism of mononuclear lymphocytes in children with infectious mononucleosis. Infectious Diseases. 2004;2(4):17-21. (in Russian).
Copyright (c) 2018 ACTUAL INFECTOLOGY
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.